首页> 外文期刊>Journal of viral hepatitis. >Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
【24h】

Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.

机译:丙型肝炎病毒和人类免疫缺陷病毒合并感染的治疗:从大型试验到现实生活。

获取原文
获取原文并翻译 | 示例
           

摘要

To analyse the barriers for anti-hepatitis C virus (anti-HCV) treatment in human immunodeficiency virus (HIV)-HCV coinfected patients, we surveyed 71 physicians specializing in infectious disease (39%), internal medicine (27%), HIV/AIDS information and care (17%), haematology (10%) and hepatology (6%). A standard data collection form was used to identify patients observed in 7 days in November 2004. Three hundred and eighty patients with the following characteristics were included: male gender 71%; mean age 41.5 years; HIV diagnosed 12 years ago; routes of transmission via injection drug use (78%); undetectable HIV viral load (235/373, 63%) or <10 000 copies/mL (86/373, 23%). HCV RNA was positive in 325 of 369 (88%) patients; HCV genotype was 1 or 4 in 65% and liver biopsy had been carried out in 56%. There were several explanations for the nontreatment of HCV in 205 of the 380 (54%) patients, with 2.4 reasons per patient: anti-HCV treatment was deemed questionable (n = 109) because of minor hepatic lesions, alcohol consumption, or active drug use; no liver biopsy had been performed (n = 68); treatment was contraindicated (n = 62), mainly for psychiatric reasons; there was physician conviction of poor patient compliance (n = 62) and patient refusal (n = 33). Patients having received anti-HCV treatment (n = 91) compared with those who had never received any (n = 205) were more commonly of European origin, had better control of their HIV infection, were followed by a hepatologist more often, had a liver biopsy more often and had more commonly a high HCV viral load (P < 0.001). In 'real life' in France in 2004, more than half of the HIV-HCV coinfected patients have never received anti-HCV treatment. The main reasons are a treatment that may be deemed questionable (minimal hepatic lesions, alcohol, active drug use), a lack of available liver biopsy, a psychiatric contraindication and physician conviction of poor patient compliance.
机译:为了分析在人类免疫缺陷病毒(HIV)-HCV合并感染的患者中抗丙型肝炎病毒(anti-HCV)治疗的障碍,我们调查了71位专攻传染病(39%),内科(27%),HIV /艾滋病信息和护理(17%),血液学(10%)和肝病学(6%)。使用标准数据收集表来识别2004年11月在7天内观察到的患者。其中包括380位具有以下特征的患者:男性71%;平均年龄41.5岁; 12年前诊断出艾滋病毒;通过注射毒品传播途径(78%);无法检测到HIV病毒载量(235 / 373,63%)或<10000拷贝/ mL(86 / 373,23%)。 369名患者中的325名(88%)HCV RNA阳性; HCV基因型的65%为1或4,肝活检的比例为56%。对于380例(54%)患者中的205例未治疗HCV有几种解释,每位患者有2.4个原因:由于较小的肝病,饮酒或使用活性药物,抗HCV治疗被认为是可疑的(n = 109)。用;未进行肝活检(n = 68);禁忌症(n = 62),主要是由于精神病学原因;医生认为患者依从性差(n = 62)和患者拒绝(n = 33)。与从未接受过抗HCV治疗的患者(n = 205)相比,接受抗HCV治疗的患者(n = 205)更常见于欧洲血统,对HIV感染的控制更好,其次是肝脏科医生,肝活检的频率更高,HCV病毒载量更高(P <0.001)。在2004年法国的“现实生活”中,一半以上的HIV-HCV合并感染患者从未接受过抗HCV治疗。主要原因是可能被认为有问题的治疗方法(最小的肝病灶,酒精,有效药物使用),缺乏可用的肝活检,精神病禁忌症以及医生认为患者依从性差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号